Streetbeat News

Earnings

Franklin Covey (NYSE:FC) reported Q2 earnings of $0.06 per share, beating estimates by 20% but showing a 50% decrease from last year. Sales of $61.34M missed estimates by 1.10%, a slight decrease from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 27, 2024 | 8:38 pm

DTI

Drilling Tools Intl (NASDAQ:DTI) reported a significant decrease in Q4 earnings per share, down to $0.13 from $0.35 YoY, and a slight decrease in sales to $35.19M from $36.66M YoY.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 8:37 pm

VRNT

Verint has projected its FY25 earnings per share (EPS) to be around $2.89, slightly above the estimated $2.84. However, its revenue forecast of $930 million, with a possible 2% variance, falls short of the expected $951.8 million.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:36 pm

VRNT

Verint Systems (NASDAQ:VRNT) reported Q4 2024 earnings with a GAAP EPS of $0.37, missing the $0.47 estimate, but sales of $265.109M exceeded the $263.116M estimate, marking an 11.98% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:35 pm

BNTX

MTNB

RHHBY

Matinas BioPharma reported a FY23 EPS of $(0.11), a slight decrease from $(0.10) YoY. Revenue for 2023 was $1.1 million, down from $3.2 million in 2022, primarily from collaborations with BioNTech SE and Genentech Inc. Total costs and expenses decreased to $24.9 million from $27.8 million. The net loss widened to $22.9 million from $21.0 million. Cash reserves at the end of 2023 stood at $13.8 million, down from $28.8 million, with projections indicating sufficient funds through Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:34 pm

IPSEY

MACK

Merrimack Pharmaceuticals received a $225 million milestone payment from Ipsen for FDA approval of ONIVYDE for metastatic adenocarcinoma of the pancreas. Merrimack's Board sees no further payments from Ipsen or Elevation Oncology agreements likely and plans a dissolution meeting for May 10, 2024, to discuss a liquidating dividend.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:34 pm

AVTX

BIOR

GLYC

SSKN

In Wednesday's after-market session, health care stocks saw significant movements. Avalo Therapeutics (AVTX) led the gainers with a 215.8% increase to $15.0, while Strata Skin Sciences (SSKN) led the losers with a 12.5% decrease to $0.39. Other notable movers included Fresh2 Group (FRES), Biora Therapeutics (BIOR), and GlycoMimetics (GLYC), with their stock prices also experiencing changes due to various factors including Q4 earnings reports.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:31 pm

RUM

Rumble Inc (NASDAQ:RUM) reported Q4 earnings with a revenue of $20.39 million, missing the consensus estimate of $28.1 million but beating EPS estimates with a loss of 14 cents per share against an expected loss of 22 cents. The company saw a 16% quarter-over-quarter increase in monthly active users, reaching 67 million, with 48 million from the US and Canada. Average minutes watched per month slightly decreased, while hours of uploaded video per day increased year-over-year. Rumble highlighted its new products, including Rumble Cloud, and partnerships, such as with Barstool Sports. The company expects revenue growth starting Q2 of 2024 and aims for breakeven in 2025.

Portfolio Pulse from Chris Katje

March 27, 2024 | 8:31 pm

AQMS

BTM

MLKN

NVVE

SGBX

In Wednesday's after-market session, several industrials stocks saw significant movements. Safe & Green Holdings, Nuvve Holding, Bitcoin Depot, Tritium DCFC, iSun, and Advent Technologies Holdings were among the gainers, with increases ranging from 2.21% to 10.3%. On the losing side, MillerKnoll, Urban-gro, Aqua Metals, Simpple, Velo3D, and Vertical Aerospace experienced declines between 4.28% and 14.9%. Notably, earnings reports influenced some of these movements.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:31 pm

FDX

Financial analysis reveals a surge in options activity for FedEx (NYSE:FDX), with a bearish sentiment prevailing among traders. The analysis highlighted 17 unusual trades, with a mix of bullish and bearish positions, and a notable price window from $135.0 to $305.0 for FedEx's stock. The current trading volume and a slight price decrease are observed, alongside an upcoming earnings release in 83 days. FedEx's significant role in express package delivery and its financial performance are also discussed.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:31 pm